Abstract
Introduction: Nail psoriasis occurs in 50-70% of patients with psoriasis (PsO) and 60-80% of patients with psoriatic arthritis (PsA). Here, we report efficacy results of secukinumab in nail psoriasis from TRANSFIGURE trial in PsO patients, FUTURE program in PsA patients, and MAXIMISE trial in axial PsA patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
